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Background: To examine the relationship between human papillomavirus (HPV) and giant cell arteritis (GCA) of the
temporal artery.
Methods: The study group consisted of 22 cases of histologically positive/biopsy confirmed GCA. The control
groups consisted of 21 histologically negative temporal artery biopsies and fifteen cases of vascular margins of
nephrectomies. For detection of the presence of HPV, two methods were used: 1) polymerase chain reaction (PCR)
with INNO-LiPA HPV Genotyping Extra, 2) Cervista™ HPV HR. All cases were from the files of the Barnes-Jewish
Hospital and Washington University in St. Louis.
Results: HPV DNA was detected by PCR and genotyping in 16 of 22 (73%) histologically positive cases of GCA and
in only five of 21 (24%) histologically negative temporal artery biopsies. Among the vascular margin controls, only
three of 15 (20%) were positive for HPV DNA. The second, independent method (CervistaTM) confirmed the
aforesaid results with 100% concordance with the exception of three cases which had low genomic DNA for which
it was not possible to perform the test. The differences in HPV positivity between the histologically positive and
negative temporal artery biopsies and between the histologically positive temporal artery biopsies and controls
were both statistically significant (p = 0.001 and 0.002, respectively).
Conclusions: The results of our study revealed a statistically significant association between HPV positivity and
biopsy confirmed temporal giant cell arteritis GCA (p = 0.001). Further studies are necessary to elucidate the
pathophysiology underlying this association.
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Giant cell arteritis is one of the most common causes of
vasculitis involving the temporal artery. Other potential
causes are Wegener granulomatosis, polyarteritis nodosa
(PAN), and Buerger disease [1]. GCA generally affects
individuals over 55 years of age (with a mean age at
diagnosis of approximately 72 years) [2] with an annual
incidence of approximately 18 per 100,000 in persons
aged 50 years or older.
Histologically, GCA shows transmural inflammation
with mixed inflammatory cell infiltrate mostly consisting
of lymphocytes, histiocytes, plasma cells, occasional neu-
trophils and rarely eosinophils (Figure 1). This causes* Correspondence: amir.mohammadi@jax.ufl.edu
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distribution, and reproduction in any mediumdestruction of the vessel's internal elastic lamina which
is best demonstrated with elastic stains such as
Verhoeff-Van Gieson (Figure 2) or Movat pentachrome.
The presence of giant cells, next to the elastic lamina in
particular, is the classic and pathognomonic feature of
GCA. However, this is present in only about 50% of
biopsy-proven cases.
Infectious agents have long been considered as a pos-
sible etiology of GCA. The concept is that GCA repre-
sents a chronic inflammatory response, triggered by an
infectious agent, with subsequent inappropriate tissue
response to injury. However, studies looking for organ-
isms have had conflicting results. Some have demon-
strated organism DNA, such as Herpes Simplex Virus,
while the vast majority have failed to demonstrate an as-
sociation. It is speculated that the inflammatory re-
sponse may be triggered by an infectious agent. If aentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Biopsy of temporal artery showing a transmural
mixed inflammatory cell infiltrate with intimal thickening, and
fragmentation and distortion of the internal elastic lamina (H &
E, original magnification x40).
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established, the potential clinical implications are great,
as GCA, with its possible vision loss [3-5], polymyalgia
rheumatica and even eventually ischemic stroke [6-9],
might potentially be prevented by vaccination or other
strategies.
Human papillomavirus (HPV) is an increasingly com-
mon human pathogen in recent decades. It is a mucoso-
tropic virus which is not thought of as spreading
systemically. However, HPV genotype 16 has been found
integrated into the genome of bacteria isolated from cer-
vical cancer biopsies, and there is also published data
showing HPV viral particles within peripheral nervesFigure 2 Elastic stains on the same case of histologically positive
temporal artery biopsy as shown in Figure 1, showing the
fragmentation, distortion and lack of continuity of the internal
elastic lamina, a characteristic feature of temporal arteritis
(Verhoeff-Van Gieson staining; original magnification, X40).and small vascular endothelial cells adjacent to oral and
cervical cancers as demonstrated by transmission elec-
tron microscopy [7,10]. In this study, we sought to de-
termine if there is an association between GCA and
HPV.
Methods
With approval by the Washington University Human
Research Protection Office (HRPO), we searched the
Copath database of Barnes Jewish Hospital for temporal
artery biopsy specimens from 1995 to 2008 and retrieved
all specimens for which material was available. We iden-
tified approximately 60 cases, of which 43, (22 histologi-
cally positive and 21 histologically negative) had material
available for review. There were five males and 17
females in the histologically positive GCA group with a
mean age of 78.9 years. In the histologically negative
group, there were four males and 17 females with a
mean age of 67 years, and the control kidney vascular
margin group had six males and nine females with a
mean age of 38.2 years. There were no statistically sig-
nificant difference in gender among the groups
(p = 0.176). The clinical diagnosis of GCA was based on
the criteria of the American College of Rheumatology
[11]. However, for our study, we considered the gold
standard to be histologic evidence of temporal arteritis.
We also randomly selected 15 renal artery vascular re-
section margins from nephrectomy specimens in
patients without any history of vasculitis for use as the
negative controls.
Two methods were utilized to evaluate for HPV DNA.
The first, INNO-LiPA HPV Genotyping Extra, was used
to perform the testing in our research laboratory of the
division of anatomic and molecular Pathology, Depart-
ment of Pathology and Immunology, Washington Uni-
versity School of Medicine, St. Louis. All blocks were
then submitted to an outside laboratory (CPA Labora-
tory, Louisville, KY) for independent preparation of gen-
omic DNA and for testing employing the CervistaTM
HPV HR (Hologic, Madison, WI, USA) assay.
In both laboratories to avoid potential contamination,
a maximum physical separation between the pre- and
post-amplification steps was used. Separate pipettes and
other lab materials were used as a part of good labora-
tory practice. The FFPE blocks were cut and processed
under strict conditions to prevent DNA from being car-
ried over from one case to the next during microtomy.
Also a new blade was used for each case and the area
was cleaned. Ice cubes used to cool blocks were dis-
carded between cases.
With regards to the technical limitations of this study,
it is well known that formalin fixation randomly frag-
ments DNA in a duration-dependent manner, resulting
in a partial degradation. The degree of fragmentation
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ditions used for fixation. Due to this degradation, FFPE
tissue is not suitable for amplification of large DNA seg-
ments. Nevertheless, PCR amplification of segments ran-
ging up to 1300 base pair has been reported. On the
other hand, incubation at an elevated temperature after
proteinase K digestion partially removes formalin cross-
linking of the DNA, improving yield as well as DNA
performance in assays. Furthermore, in one of the techni-
ques used in this study (INNO-LiPA HPV Genotyping),
short-PCR-fragment (SPF 10) primers are employed,
which amplify a 65 base pair segment of target DNA and
this testing is considered to be one of the most sensitive
PCR assays for the detection of HPV DNA.
Washington University testing
DNA extraction
DNA was extracted using PureGene Kit (Gentra, http://
www.Gentra.com) as per the manufacturer's instructions
from 10 μm sections cut from the paraffin blocks. The
concentration of the prepped DNA was measured spec-
trophotometrically using Nanodrop. Detailed procedure
information is available at their web site, but briefly, we
placed five 10 micron sections of tissue into a 1.5 mL
microcentrifuge tube and added 1.0 mL of xylene, vor-
texed, and incubated for five minutes with constant gen-
tle mixing. Then we centrifuged it for five minutes at
13,000-16,000 x g. In the fume hood, discarded by pipet-
ting the xylene supernatant and left behind the visible
pellet (tissue). We repeated this xylene wash twice. We
then added 1.0 mL 100% ethanol, vortexed, and incu-
bated five minutes with constant gentle mixing at room
temperature, centrifuged at 13,000-16,000 x g for five
minutes to pellet the tissue, and discarded the ethanol.
We repeated these ethanol washes twice. Subsequently
we added 1.0 mL 70% ethanol, gently mixed, and centri-
fuged at 13,000-16,000 x g for five minutes at 4°C,
removed all residual ethanol and allowed tissue pellet to
dry by centrifugation under vacuum for five minutes.
For cell lysis, we added 300 μl Cell Lysis Solution (Gen-
tra Puregene™ kit) and gently vortexed for 30 seconds.
Then we added three μl Puregene Proteinase K (20 mg/
ml), and mixed by inverting 25 times and incubated the
lysate at 55°C for three hours to overnight. We inverted
the tube periodically during the incubation. Then was
added three μl RNase A Solution to the cell lysate, and
mixed by inverting the tube 25 times and incubated at
37°C for 15 min to one hour. For Protein Precipitation
we cooled quickly the sample to room temperature by
placing on ice and added 100 μl Protein Precipitation
Solution (Gentra Puregene™ kit) to the cell lysate. The
volume should be 1/3 of the Cell Lysis Solution in the
tube. Subsequently, it is vortexed vigorously at high
speed for 20 seconds to mix the Protein PrecipitationSolution uniformly with the cell lysate. Then, we centri-
fuged it at 13,000-16,000 x g for five minutes. The preci-
pitated proteins formed a tight pellet. If the protein
pellet was not tight, we vortexed vigorously for 20 sec-
onds at high speed, and then incubated on ice for 5 min.
We then centrifuged at 13,000–16,000 x g for three min-
utes. Using a pipette, we removed the supernatant con-
taining the DNA (leaving behind the precipitated protein
pellet) into a clean 1.5 mL microcentrifuge tube. We
added two μl (for 400 μl supernatant) of a DNA carrier
(glycogen; to final concentration of 50-150 mcg/μl) to
aid recovery of small DNA quantities and then vortexed
them. We then added 400 μl 100% of isopropanol. Sub-
sequently, it was mixed by inverting gently ~50 times
until the white threads of DNA formed a visible clump,
and then it was centrifuged at 13,000-16,000 x g for 10
minutes and the supernatant was poured off. We added
500 μl of 70% ethanol and inverted the tube to wash the
DNA pellet. We centrifuged at 13,000-16,000 x g for 5
minutes, and carefully poured off the ethanol and
inverted and blotted the liquid from the tube on clean
absorbent paper and allowed to air dry for 10-15 min-
utes. Finally, we added 50 μl DNA Hydration Solution
and incubated at 65°C for one hour to dissolve the
DNA. We incubated at room temperature overnight
with gentle shaking. Samples could then be centrifuged
briefly and transferred to a storage tube. The concentra-
tion of the DNA used for INNO-LiPA HPV Genotyping
Extra testing in each case was 50 ng.
INNO-LiPA HPV Genotyping testing
The INNO-LiPA HPV Genotyping Extra is based on the
principle of reverse hybridization. Part of the L1 region
of the human papillomavirus (HPV) genome is amplified
using short-PCR-fragment assay (SPF10 primers), and
the resulting biotinylated amplicons are then denatured
and hybridized with specific oligonucleotide probes.
An additional primer pair for the amplification of the
human HLA-DPB1 gene is added to monitor sample
quality and extraction. The length of the HLA-DPB1
fragment is 280 base pairs. All probes are immobilized
as parallel lines on membrane strips. After hybridization
and stringent washing, streptavidin-conjugated alkaline
phosphatase is added, which binds to any biotinylated
hybrid previously formed.
Incubation with BCIP (5-Bromo-4-Chloro-3’-Indoly-
phosphate p-Toluidine Salt)/NBT (Nitro-Blue Tetrazo-
lium Chloride) chromogen yields a purple precipitate,
and the results are visually interpreted using the refer-
ence guide provided. An amplification kit (INNO-LiPA
HPV Genotyping Extra Amp) is used for standardized
preparation of biotinylated amplified material. This amp-
lification kit is based on the polymerase chain reaction
(PCR) using SPF10 primers.
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using a single typing strip on which 28 sequence-specific
DNA probe lines and 4 control lines are fixed, which
permits specific detection of 28 HPV genotypes, includ-
ing all 18 high-risk genotypes, and 10 low-risk genotypes
(HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 44,
45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 70, 71, 73, 74,
and 82) as described by the manufacturer (Figure 3).
CPA Laboratory testing
DNA extraction
Slides were cut from the original blocks, and The
QIAamp DNA FFPE Tissue kit (QIAGEN, www.qiagen.
com) was used for purification of genomic DNA from
formalin-fixed, paraffin-embedded tissues according to
the manufacturer’s instructions with exception of incu-
bation time. Overnight incubation in proteinase K for di-
gestion of proteins/contaminants is not recommended
by Qiagen but is something that CPA Laboratory has
found useful to increase the nucleic acid elution.
Briefly, the QIAamp DNA FFPE Tissue procedure
consisted of several steps including removal of paraffin
from slides using xylene, subsequent specimen lysis
under denaturing conditions with proteinase K, incuba-
tion at 90°C to reverse all formalin cross-linking, andFigure 3 INNO-LiPA typing on 16 patients. Strips # 5, 9, 11, 14, 15 an
hybridization. The line patterns (corresponding to # 3 of the probe side b
correspond with HPV type 16.DNA binding to the membrane for removal of contami-
nants. Residual contaminants were washed away and
pure, concentrated DNA was eluted from the
membrane.CervistaTM HPV HR testing
CervistaTM HPV HR [12] is a qualitative, diagnostic test
for the detection of DNA from 14 high-risk HPV types
(i.e., types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, and 68). The CervistaTM HPV HR test uses the Inva-
derW chemistry which is a signal amplification technique
for detection of specific nucleic acid sequences. In this
method two types of isothermal reactions are used: a
primary reaction that occurs on the targeted DNA se-
quence and a secondary reaction that produces a fluor-
escent signal. During the primary reaction, two types of
sequence specific oligonucleotides (i.e. a probe oligo-
nucleotide and an InvaderW oligonucleotide) bind to the
target DNA recognition site. When those sequence spe-
cific oligonucleotides overlap by at least one base pair
on the target sequence, an invasive structure forms that
acts as a substrate for the CleavaseW enzyme. The en-
zyme cleaves the 5’ portion (flap) of the probe at the
position of the overlap.d 16 are positive because they show clearly visible lines of
ars) were compared to the interpretation chart supplied with the kit
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rapidly on and off the target sequence generating many
cleaved 5’ flaps per target sequence. The cleaved flaps
then bind to a universal hairpin fluorescence resonance
energy transfer (FRET) oligonucleotide creating another
invasive structure that the CleavaseW enzyme recognizes
as a substrate. The enzyme cleaves the FRET oligonu-
cleotides between the fluorophore and quencher mol-
ecule and produces a fluorescence signal as the cleaved
flaps cycle on and off. For each copy of target, the com-
bined primary and secondary reactions result in 106–
107 fold signal amplification per hour. The reagents for
this test are provided as three oligonucleotide master
mixtures, which identify the 14 types of HPV arranged
according to phylogenetic relatedness. Master mixture 1
identifies the positivity of genotypes 51, 56 and 66
(MM1: HPV 51, 56 and 66). Master mixture 2 (MM2)
shows the positivity of genotypes HPV 18, 39, 45, 59 and
68 and master mixture 3 (MM3) reveals the positivity of
HPV genotypes 16, 31, 33, 35, 52 and 58. By design, the
released 5'-flaps bind only to their respective FRET oli-
gonucleotides to generate target-specific signal. A posi-
tive result indicates that at least one of the 14 high-risk
types is present in the DNA sample. For each case 150
to 200 ng of DNA prepped from the FFPE tissues at
CPA Labs were utilized for the Cervista HPV testing.
The sensitivity of this test is set at 5000 copies of HPV
DNA. The Cervista assay has an internal control to ver-
ify if the assay worked. If the internal control does not
pass, it suggests either the sample is degraded or extrac-
tion failed or the PCR did not work.
Statistics
Statistical analyses were performed using the Chi-Square,
T-test and Fisher's exact tests to evaluate the correlation
between the presence of HPV DNA and other variables.
P values< 0.05 were considered significant. All statistical
analyses were performed using the SAS v.9.1 system soft-
ware (SAS Institute Inc., Cary, NC).
Results
Using the INNO-LiPA HPV Genotyping Extra, 16 of the
22 (17 female and 5 male) biopsy-confirmed GCA cases
were positive for HPV. Twelve out of the 16 (75%) HPV-
positive GCA-positive patients were female. Among
these 16 positive cases, 5 had a HPV 6 alone (31%), 3
cases had HPV 16 alone (19%), 7 cases had both types 6
and 16 (44%), and only one case was extensively "multi-
genotype" showing types 6, 16, 31, 33, and 40 (6%) (Test-
ing results are presented in Tables 1 and 2). In all cases
where HPV was detected, type 6, type 16, or both were
present (100%). The cases were also tested by the Cer-
vistaTM HPV HR assay for confirmation, which only
evaluates for high risk HPV types (not for HPVs 6 and11). Two cases which were HPV type 6 by INNO-LiPA
(cases # 4 and 6) had low genomic DNA when prepped
for the CervistaTM HPV HR testing, so could not be
evaluated by this method. All positive cases of the Cer-
vistaTM HPV HR were from the Master Mix 3 which
includes the HPV genotypes 16, 31, 33, 35, 52 and 58.
As expected, all cases for which genotype 6 was present
in the INNO-LiPA method were negative with the Cer-
vista method since low risk types are not evaluated in
that assay. All negative cases with INNO-LiPA HPV
Genotyping Extra were negative also with CervistaTM
HPV HR testing. As such, there was 100% agreement be-
tween the two testing methods on the histologically
positive temporal arteritis cases.
Among the 21 cases of GCA histologically negative bi-
opsies, 5 were positive for HPV by INNO-LiPA HPV
Genotyping Extra, of which 3 (60%) were genotype 16,
one (20%) was genotype 6 and one (20%) was genotype
52. CervistaTM HPV HR testing revealed positivity of
Master Mix 3 for all 4 cases which were positive by
INNO-LiPA HPV Genotyping Extra for high risk HPV.
Case number 2 which was negative with INNO-LiPA
was of low genomic DNA with Cervista method. As
such, there was 100% agreement between the two testing
methods on the histologically negative temporal artery
biopsy cases.
Among the 15 nephrectomy vascular resection mar-
gins (controls), 3 were positive for HPV by INNO-LiPA
HPV Genotyping Extra. Two cases showed genotype 16
(1 case of Wilms' tumor and 1 of acute and chronic py-
elonephritis), and one genotype 6 (a case of papillary
urothelial carcinoma). CervistaTM HPV HR testing
revealed positivity of Master Mix 3 for both cases which
were positive for high risk HPV by INNO-LiPA HPV
Genotyping Extra. As such, there was 100% agreement
between the two testing methods on the 15 vascular
margin control cases.
The association between HPV positivity and histologi-
cally confirmed GCA was statistically significant
(p = 0.0013). There was also a statistically significant as-
sociation between HPV positivity and Caucasian race
(p = 0.0339). No other associations were statistically
significant.
In multivariate analysis (Table 3), subjects with histo-
logically confirmed GCA had a 56-fold higher likelihood
of having HPV positivity adjusted by gender, age and
race (OR, point estimate 56.01; 95% CI 3.5-895.68).
Discussion
Giant cell (temporal) arteritis is a chronic vasculitis in-
volving medium and large size arteries that typically
affects individuals older than 50 years of age.[1,3,4] Al-
though it usually affects the superficial temporal arteries,
it can also affect the aorta, carotid, subclavian, vertebral,



















1 Neg Neg 1 Neg Neg 1 Neg Neg
2 6 Neg 2 Neg LGD 2 Neg Neg
3 Neg Neg 3 Neg Neg 3 Neg Neg
4 6 LGD 4 6 Neg 4 Neg Neg
5 6, 16, 31, 33, 40 pos MM3 5 Neg Neg 5 Neg Neg
6 6 LGD 6 52 pos MM3 6 Neg Neg
7 6 Neg 7 Neg Neg 7 Neg Neg
8 6 Neg 8 Neg Neg 8 6 Neg
9 Neg Neg 9 Neg Neg 9 16 pos MM3
10 6, 16 pos MM3 10 Neg Neg 10 Neg Neg
11 16 pos MM3 11 Neg Neg 11 16 pos MM3
12 6, 16 pos MM3 12 Neg Neg 12 Neg Neg
13 16 pos MM3 13 Neg Neg 13 Neg Neg
14 6, 16 pos MM3 14 Neg Neg 14 Neg Neg
15 Neg Neg 15 Neg Neg 15 Neg Neg
16 Neg Neg 16 16 pos MM3
17 Neg Neg 17 Neg Neg
18 6, 16 pos MM3 18 16 pos MM3
19 6, 16 pos MM3 19 Neg Neg
20 6, 16 pos MM3 20 16 pos MM3
21 16 pos MM3 21 Neg Neg
22 6, 16 pos MM3
LGD: Low Genomic DNA.
POS MM3: Positive in Master Mix 3.
HPV=Human papillomavirus.
MM1: HPV types 51, 56 and 66.
MM2: HPV types 18, 39, 45, 59 and 68.
MM3: HPV types 16, 31, 33, 35, 52 and 58.
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inflammation with multinucleated giant cells is observed
in approximately 50% of the patients.
Histologically, the disease progresses from minimal
involvement of vessels, with only collections of lym-
phocytes confined to the internal or external elastic
lamina or adventitia to a panarteritis with segmental
areas of necrosis of the arterial wall and extensive de-
struction of the elastic laminae, a feature that can beTable 2 Correlation between the three study groups for HPV
Biopsy Positive GCA* Biopsy Neg
HPV Positive 16 (73%) 5 (24
HPV Negative 6 (27%) 16 (7
Total 22 21
*Differences between biopsy positive and biopsy negative cases and between biop
respectively).
**Difference between biopsy negative and control cases was not statistically signific
GCA= giant cell arteritis; HPV=human papillomavirus.clearly demonstrated with special stains for elastic
fibers (Figures 1 and 2).
The etiology of the inflammatory reaction in the GCA
has not been identified. However, it has been demon-
strated that there is a restricted clonal expansion of
tissue-infiltrating T cells in these lesions, which suggests
that they are reacting to a specific antigen located within
the affected arterial wall which is thus eliciting the dis-
ease [13]. The most recent hypothesis regarding thetest results





6%) 22 (51%) 12
43 15
sy positive and control cases were statistically significant ((p = 0.001 and 0.002,
ant (p = 0.79).
Table 3 Odds Ratios for variable and presence of










HPV 56.014 3.503 895.681
Age 1.196 1.053 1.358
HPV= human papillomavirus.
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injury (maybe due to infection) leads to an inappropriate
activation of T-cell-mediated immunity [14,15]. The sub-
sequent release of inflammatory mediators within the ar-
terial vessel wall can attract macrophages which then
become multinucleated giant cells, creating the charac-
teristic histology of this disease and also leading to an
oligoclonal expansion of T-cells directed against antigens
within or near the elastic lamina. This cascade of events
in due course results in vessel wall damage, intimal
hyperplasia, and eventual stenotic occlusion.
Infectious agents have been considered in the past as
the etiology of GCA. Elling et al., by indirect serological
evidence, found high incidence of GCA within a popula-
tion associated with Chlamydia pneumoniae, Myco-
plasma pneumoniae, and Parvovirus B19 [16]. Published
data from Wagner et al. [15] and Powers et al. [17]
reported a relationship between GCA, C. pneumonia
and herpes simplex virus (HSV). However, further stud-
ies were unable to detect the presence of these infectious
agents. Cooper et al. [14] and Cankovic and Zarbo [18],
could not confirm the association between GCA and C.
pneumonia, HSV, varicella zoster virus (VZV), Epstein–
Barr virus (EBV), or human herpesvirus 7 (HHV7). In
addition, Rodriguez-Pla et al. [19], Helweg-Larsen [20]
and other authors [21-23] could not confirm the pres-
ence of herpes viruses, varicella zoster virus, parvovirus,
or C. pneumoniae in temporal artery GCA. Due to this
conflicting and contradictory data, no conclusive link
has, to date, been demonstrated between a GCA and a
specific infectious agent.
The role of human papillomavirus (HPV) in the devel-
opment of cervical, head and neck, anal and skin cancers
is well known. Molecular and epidemiological studies
have shown that persistent HPV infection is the most
important risk factor for cervical cancer [24,25]. High
risk HPV also has an important role in anogenital and
oropharyngeal squamous cell carcinoma [26]. They are
also implicated with skin cancer in individuals with epi-
dermodysplasia verruciformis [27] and can induce a var-
iety of proliferative lesions, such as warts and laryngealpapillomas. There are very few associations between
HPV and non-neoplastic diseases.
Interestingly, Ma et al. [10] reported the presence of
HPV type 16 in the genome of bacterial strains (Entero-
coccus, Staphylococcus, Bacillus and Corynebacterium)
and demonstrated the HPV viral particles by transmis-
sion electron microscopy in those bacteria. In addition,
HPV type 16 has been detected in peripheral nerves,
and vascular endothelial cells [7]. Another possible path-
way is for HPV to disseminate systemically. This has
long been debated [28]. The role of viremia in the
pathogenesis of HPV-related diseases is still unclear, al-
though HPV DNA has been detected in peripheral blood
in some studies, though in varying amounts [29-32].
In this study, we found that HPV DNA, of both high
and low risk types, is present in formalin-fixed,
paraffin-embedded temporal artery biopsy specimens,
and in statistically significantly higher numbers in the
arteritis specimens compared to histologically-negative
temporal artery biopsies and nephrectomy vascular mar-
gin controls. The validity of these results was confirmed
with exactly matching results by an outside laboratory
that independently prepped DNA from the paraffin
blocks and utilized a completely different detection
method. Our results are admittedly surprising and bring
many questions about what HPV's role, if any, would be
in temporal arteritis. HPV has been associated with
tumorigenesis, and many studies have investigated HPV-
related modification of the immune system to establish
infection. However, we are not aware of any literature
citing HPV as an inciting agent for inflammatory dis-
eases. Our findings do support the notion that HPV can
disseminate systemically, but do not, by themselves, tell
us anything specific about the pathophysiological rela-
tionship between the virus and temporal arteritis, if
there even is one. Further studies are necessary to ad-
dress this.
It is important to mention that a negative temporal ar-
tery biopsy does not rule out the diagnosis of temporal
artery GCA, since the changes can be patchy with skip
areas of uninvolved artery. Although serial sectioning of
the temporal artery biopsy is recommended, not all cases
will be diagnosed histologically [33]. Actually, after re-
view of the medical records of five of our biopsy-
negative HPV-positive cases, in one case, the patient
showed dramatic improvement after treatment with ster-
oids (possible false negative case which was not included
as a HPV-positive case in our statistical analysis).
It is also worth noting that of the 16 histologically-
proven GCA cases that had HPV, 11 were high risk
genotype 16. Only five cases were positive for low risk
HPV genotype 6. Although, the importance of distin-
guishing low risk from high risk HPV genotypes has
been established in the pathogenesis of neoplasms, what
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as GCA is currently unknown.
Conclusion
In summary, we have identified HPV DNA in the major-
ity of histologically-proven giant cell (temporal) arteritis
specimens and validated these results by a completely
independent outside laboratory assay. The association
raises questions regarding the biology of HPV infections,
when dissemination occurs, and what this dissemination
means clinically. Such studies are required to understand
the significance of the association in our series.
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